Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD | MicrobiomeTrials← Back to trialsNCT07652294
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
ENROLLING_BY_INVITATIONPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-08Est. Completion: 2029-03-02
Enrollment target: 645 participants Locations- Study Site 002, San Antonio, Texas, United States
Other microbiome trials you might be interested in
Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis
Background:
Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in …
Bethesda, United StatesEst. completion Jun 1, 2036
Ulcerative Colitis (UC)Crohn Disease (CD)
Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by recurrent intestinal inflammatio…
Jakarta Pusat, IndonesiaCompleted Jan 19, 2026
The gut microbiota comprises all microorganisms inhabiting the digestive tract, evolving throughout life under the influ…
Bruz, FranceEst. completion Jul 1, 2026